Charles River Laboratories International Inc (CRL)
195.77
+1.58
(+0.81%)
USD |
NYSE |
Nov 22, 16:00
195.80
+0.03
(+0.02%)
After-Hours: 20:00
Charles River Laboratories International Net Income (Quarterly): 68.68M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 68.68M |
| June 30, 2024 | 89.99M |
| March 31, 2024 | 67.33M |
| December 31, 2023 | 187.08M |
| September 30, 2023 | 87.39M |
| June 30, 2023 | 97.02M |
| March 31, 2023 | 103.13M |
| December 31, 2022 | 187.41M |
| September 30, 2022 | 96.47M |
| June 30, 2022 | 109.32M |
| March 31, 2022 | 93.02M |
| December 31, 2021 | 137.58M |
| September 30, 2021 | 103.43M |
| June 30, 2021 | 88.45M |
| March 31, 2021 | 61.53M |
| December 31, 2020 | 143.19M |
| September 30, 2020 | 102.91M |
| June 30, 2020 | 67.44M |
| March 31, 2020 | 50.77M |
| December 31, 2019 | 80.35M |
| September 30, 2019 | 72.81M |
| June 30, 2019 | 43.73M |
| March 31, 2019 | 55.13M |
| December 31, 2018 | 59.66M |
| September 30, 2018 | 60.37M |
| Date | Value |
|---|---|
| June 30, 2018 | 53.71M |
| March 31, 2018 | 52.63M |
| December 31, 2017 | -29.85M |
| September 30, 2017 | 52.47M |
| June 30, 2017 | 53.95M |
| March 31, 2017 | 46.78M |
| December 31, 2016 | 44.68M |
| September 30, 2016 | 37.74M |
| June 30, 2016 | 35.21M |
| March 31, 2016 | 37.14M |
| December 31, 2015 | 31.88M |
| September 30, 2015 | 37.38M |
| June 30, 2015 | 48.51M |
| March 31, 2015 | 31.54M |
| December 31, 2014 | 27.17M |
| September 30, 2014 | 32.04M |
| June 30, 2014 | 35.26M |
| March 31, 2014 | 32.23M |
| December 31, 2013 | 19.10M |
| September 30, 2013 | 30.87M |
| June 30, 2013 | 27.28M |
| March 31, 2013 | 25.58M |
| December 31, 2012 | 18.42M |
| September 30, 2012 | 21.97M |
| June 30, 2012 | 30.47M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
50.77M
Minimum
Mar 2020
187.41M
Maximum
Dec 2022
101.12M
Average
94.75M
Median
Net Income (Quarterly) Benchmarks
| Boston Scientific Corp | 468.00M |
| CVS Health Corp | 87.00M |
| Arbutus Biopharma Corp | -19.72M |
| FibroBiologics Inc | -0.50M |
| Biomarin Pharmaceutical Inc | 106.08M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.010B |
| Total Expenses (Quarterly) | 892.36M |
| EPS Diluted (Quarterly) | 1.33 |
| Enterprise Value | 12.17B |
| Gross Profit Margin (Quarterly) | 34.56% |
| Profit Margin (Quarterly) | 6.80% |
| Earnings Yield | 4.09% |
| Operating Earnings Yield | 5.22% |
| Normalized Earnings Yield | 4.092 |